

ASX Announcement 14 June 2017

Boardroom Media Interview: Positive Full Year Results Expected

ITL Health Group is pleased to provide the opportunity to listen to an audio interview with Mr Bill Mobbs, Executive Chairman.

Mr Mobbs talks about the Trading Update issued today which states that ITL expects to announce very positive results for the financial year to 30th June 2017.

Click here for the Boardroom Media interview:

http://boardroom.media/broadcast/preview/?refid=&eid=593f7f256f8db701be 9db376

ITL Health Group

ITL is an innovative global medical technology company made up of four divisions; ITL BioMedical, ITL Healthcare, ITL Clinical & MyHealthTest.

ITL creates & manufactures leading edge medical devices for the clinical, blood banking, & laboratory markets & is a growing provider of specialist ancillary products for the blood culture testing market.

ITL holds an IP portfolio of 48 patents & sells into

MyHealthTest creates and markets highly innovative direct to consumer pathology testing for major chronic diseases.



Ranked 16th most Innovative Company by the AFR **Innovative Companies Awards**

Australian Securities Exchange

Code: ITD

Ordinary Shares

95,928,314

Board of Directors

Bill Mobbs Mark Peatey Andrew Turnbull Executive Chairman Non-executive Director Non-executive Director

Trevor Doolan Chief Financial Officer &

Company Secretary

ITL Contact

Trevor Doolan Phone: Email: Address

Company Secretary +61 3 8773 3050 info@itl-limited.com Unit 1, 63 Wells Road Chelsea Heights. Victoria, 3196

www.itlhealthgroup.com

Media

Walbrook IR Ben Knowles +61 426 277 760 Phone:

ben.knowles@walbrookir.com.au Email: